English
简体中文
Total: £ 56.28
Published Date: 2024-11-25 | Pages: 166 | Tables: 293 | Pharma & Healthcare
Anti-angiogenic ophthalmic agents act as antagonists against the vascular endothelial growth factor (VEGF). When retinal pigment cells become ischemic and dry up VEGF stimulates generation of new blood vessels by a process called neovascularization. If new blood vessels are not generated properly, leakage occurs in retina, which leads to vision loss. Angiogenesis plays an important role in chronic inflammation and fibrosis, tumor growth and vascularization of ischemic tissue.
The global market for Angiogenesis Therapeutic Agent was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for Angiogenesis Therapeutic Agent was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Angiogenesis Therapeutic Agent was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Angiogenesis Therapeutic Agent was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Angiogenesis Therapeutic Agent include Gilead Sciences, Inc., Eyetech Inc., Becton, Dickinson and Company, Regeneron Pharmaceuticals, Inc., Genentech, Inc., Novartis AG, Allergan plc, Bayer AG and Santen Pharmaceutical Co., Ltd., etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Angiogenesis Therapeutic Agent, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Angiogenesis Therapeutic Agent by region & country, by Type, and by Application.
The Angiogenesis Therapeutic Agent market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Angiogenesis Therapeutic Agent.
Market Segmentation
By Company
Gilead Sciences, Inc.
Eyetech Inc.
Becton, Dickinson and Company
Regeneron Pharmaceuticals, Inc.
Genentech, Inc.
Novartis AG
Allergan plc
Bayer AG
Santen Pharmaceutical Co., Ltd.
Shanghai Pharmaceuticals
Johnson & Johnson
Pfizer
Sun Pharma
Otsuka Pharmaceutical Co. Ltd
Daiichi Sankyo
ERC Labs
Medicom Health care
Implandata ophthalmic products GmbH
The Geuder Group, MORCHER GmbH
Novamedika
Segment by Type:
Myopic Choroidal Neovascularization
Macular Edema
Diabetic Retinopathy
Macular Degeneration
Segment by Application
Retail Pharmacies
Online Pharmacies
Hospital Pharmacies
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Angiogenesis Therapeutic Agent manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Angiogenesis Therapeutic Agent in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Angiogenesis Therapeutic Agent in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Market Overview
1.1 Angiogenesis Therapeutic Agent Product Introduction
1.2 Global Angiogenesis Therapeutic Agent Market Size Forecast
1.2.1 Global Angiogenesis Therapeutic Agent Sales Value (2019-2030)
1.2.2 Global Angiogenesis Therapeutic Agent Sales Volume (2019-2030)
1.2.3 Global Angiogenesis Therapeutic Agent Sales Price (2019-2030)
1.3 Angiogenesis Therapeutic Agent Market Trends & Drivers
1.3.1 Angiogenesis Therapeutic Agent Industry Trends
1.3.2 Angiogenesis Therapeutic Agent Market Drivers & Opportunity
1.3.3 Angiogenesis Therapeutic Agent Market Challenges
1.3.4 Angiogenesis Therapeutic Agent Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Angiogenesis Therapeutic Agent Players Revenue Ranking (2023)
2.2 Global Angiogenesis Therapeutic Agent Revenue by Company (2019-2024)
2.3 Global Angiogenesis Therapeutic Agent Players Sales Volume Ranking (2023)
2.4 Global Angiogenesis Therapeutic Agent Sales Volume by Company Players (2019-2024)
2.5 Global Angiogenesis Therapeutic Agent Average Price by Company (2019-2024)
2.6 Key Manufacturers Angiogenesis Therapeutic Agent Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Angiogenesis Therapeutic Agent Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Angiogenesis Therapeutic Agent
2.9 Angiogenesis Therapeutic Agent Market Competitive Analysis
2.9.1 Angiogenesis Therapeutic Agent Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Angiogenesis Therapeutic Agent Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Angiogenesis Therapeutic Agent as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Myopic Choroidal Neovascularization
3.1.2 Macular Edema
3.1.3 Diabetic Retinopathy
3.1.4 Macular Degeneration
3.2 Global Angiogenesis Therapeutic Agent Sales Value by Type
3.2.1 Global Angiogenesis Therapeutic Agent Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Angiogenesis Therapeutic Agent Sales Value, by Type (2019-2030)
3.2.3 Global Angiogenesis Therapeutic Agent Sales Value, by Type (%) (2019-2030)
3.3 Global Angiogenesis Therapeutic Agent Sales Volume by Type
3.3.1 Global Angiogenesis Therapeutic Agent Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Angiogenesis Therapeutic Agent Sales Volume, by Type (2019-2030)
3.3.3 Global Angiogenesis Therapeutic Agent Sales Volume, by Type (%) (2019-2030)
3.4 Global Angiogenesis Therapeutic Agent Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Retail Pharmacies
4.1.2 Online Pharmacies
4.1.3 Hospital Pharmacies
4.2 Global Angiogenesis Therapeutic Agent Sales Value by Application
4.2.1 Global Angiogenesis Therapeutic Agent Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Angiogenesis Therapeutic Agent Sales Value, by Application (2019-2030)
4.2.3 Global Angiogenesis Therapeutic Agent Sales Value, by Application (%) (2019-2030)
4.3 Global Angiogenesis Therapeutic Agent Sales Volume by Application
4.3.1 Global Angiogenesis Therapeutic Agent Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Angiogenesis Therapeutic Agent Sales Volume, by Application (2019-2030)
4.3.3 Global Angiogenesis Therapeutic Agent Sales Volume, by Application (%) (2019-2030)
4.4 Global Angiogenesis Therapeutic Agent Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Angiogenesis Therapeutic Agent Sales Value by Region
5.1.1 Global Angiogenesis Therapeutic Agent Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Angiogenesis Therapeutic Agent Sales Value by Region (2019-2024)
5.1.3 Global Angiogenesis Therapeutic Agent Sales Value by Region (2025-2030)
5.1.4 Global Angiogenesis Therapeutic Agent Sales Value by Region (%), (2019-2030)
5.2 Global Angiogenesis Therapeutic Agent Sales Volume by Region
5.2.1 Global Angiogenesis Therapeutic Agent Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Angiogenesis Therapeutic Agent Sales Volume by Region (2019-2024)
5.2.3 Global Angiogenesis Therapeutic Agent Sales Volume by Region (2025-2030)
5.2.4 Global Angiogenesis Therapeutic Agent Sales Volume by Region (%), (2019-2030)
5.3 Global Angiogenesis Therapeutic Agent Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Angiogenesis Therapeutic Agent Sales Value, 2019-2030
5.4.2 North America Angiogenesis Therapeutic Agent Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Angiogenesis Therapeutic Agent Sales Value, 2019-2030
5.5.2 Europe Angiogenesis Therapeutic Agent Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Angiogenesis Therapeutic Agent Sales Value, 2019-2030
5.6.2 Asia Pacific Angiogenesis Therapeutic Agent Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Angiogenesis Therapeutic Agent Sales Value, 2019-2030
5.7.2 South America Angiogenesis Therapeutic Agent Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Angiogenesis Therapeutic Agent Sales Value, 2019-2030
5.8.2 Middle East & Africa Angiogenesis Therapeutic Agent Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Angiogenesis Therapeutic Agent Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Angiogenesis Therapeutic Agent Sales Value
6.2.1 Key Countries/Regions Angiogenesis Therapeutic Agent Sales Value, 2019-2030
6.2.2 Key Countries/Regions Angiogenesis Therapeutic Agent Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Angiogenesis Therapeutic Agent Sales Value, 2019-2030
6.3.2 United States Angiogenesis Therapeutic Agent Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Angiogenesis Therapeutic Agent Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Angiogenesis Therapeutic Agent Sales Value, 2019-2030
6.4.2 Europe Angiogenesis Therapeutic Agent Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Angiogenesis Therapeutic Agent Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Angiogenesis Therapeutic Agent Sales Value, 2019-2030
6.5.2 China Angiogenesis Therapeutic Agent Sales Value by Type (%), 2023 VS 2030
6.5.3 China Angiogenesis Therapeutic Agent Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Angiogenesis Therapeutic Agent Sales Value, 2019-2030
6.6.2 Japan Angiogenesis Therapeutic Agent Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Angiogenesis Therapeutic Agent Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Angiogenesis Therapeutic Agent Sales Value, 2019-2030
6.7.2 South Korea Angiogenesis Therapeutic Agent Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Angiogenesis Therapeutic Agent Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Angiogenesis Therapeutic Agent Sales Value, 2019-2030
6.8.2 Southeast Asia Angiogenesis Therapeutic Agent Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Angiogenesis Therapeutic Agent Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Angiogenesis Therapeutic Agent Sales Value, 2019-2030
6.9.2 India Angiogenesis Therapeutic Agent Sales Value by Type (%), 2023 VS 2030
6.9.3 India Angiogenesis Therapeutic Agent Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Gilead Sciences, Inc.
7.1.1 Gilead Sciences, Inc. Company Information
7.1.2 Gilead Sciences, Inc. Introduction and Business Overview
7.1.3 Gilead Sciences, Inc. Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Gilead Sciences, Inc. Angiogenesis Therapeutic Agent Product Offerings
7.1.5 Gilead Sciences, Inc. Recent Development
7.2 Eyetech Inc.
7.2.1 Eyetech Inc. Company Information
7.2.2 Eyetech Inc. Introduction and Business Overview
7.2.3 Eyetech Inc. Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Eyetech Inc. Angiogenesis Therapeutic Agent Product Offerings
7.2.5 Eyetech Inc. Recent Development
7.3 Becton, Dickinson and Company
7.3.1 Becton, Dickinson and Company Company Information
7.3.2 Becton, Dickinson and Company Introduction and Business Overview
7.3.3 Becton, Dickinson and Company Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Becton, Dickinson and Company Angiogenesis Therapeutic Agent Product Offerings
7.3.5 Becton, Dickinson and Company Recent Development
7.4 Regeneron Pharmaceuticals, Inc.
7.4.1 Regeneron Pharmaceuticals, Inc. Company Information
7.4.2 Regeneron Pharmaceuticals, Inc. Introduction and Business Overview
7.4.3 Regeneron Pharmaceuticals, Inc. Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Regeneron Pharmaceuticals, Inc. Angiogenesis Therapeutic Agent Product Offerings
7.4.5 Regeneron Pharmaceuticals, Inc. Recent Development
7.5 Genentech, Inc.
7.5.1 Genentech, Inc. Company Information
7.5.2 Genentech, Inc. Introduction and Business Overview
7.5.3 Genentech, Inc. Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Genentech, Inc. Angiogenesis Therapeutic Agent Product Offerings
7.5.5 Genentech, Inc. Recent Development
7.6 Novartis AG
7.6.1 Novartis AG Company Information
7.6.2 Novartis AG Introduction and Business Overview
7.6.3 Novartis AG Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Novartis AG Angiogenesis Therapeutic Agent Product Offerings
7.6.5 Novartis AG Recent Development
7.7 Allergan plc
7.7.1 Allergan plc Company Information
7.7.2 Allergan plc Introduction and Business Overview
7.7.3 Allergan plc Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Allergan plc Angiogenesis Therapeutic Agent Product Offerings
7.7.5 Allergan plc Recent Development
7.8 Bayer AG
7.8.1 Bayer AG Company Information
7.8.2 Bayer AG Introduction and Business Overview
7.8.3 Bayer AG Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Bayer AG Angiogenesis Therapeutic Agent Product Offerings
7.8.5 Bayer AG Recent Development
7.9 Santen Pharmaceutical Co., Ltd.
7.9.1 Santen Pharmaceutical Co., Ltd. Company Information
7.9.2 Santen Pharmaceutical Co., Ltd. Introduction and Business Overview
7.9.3 Santen Pharmaceutical Co., Ltd. Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2019-2024)
7.9.4 Santen Pharmaceutical Co., Ltd. Angiogenesis Therapeutic Agent Product Offerings
7.9.5 Santen Pharmaceutical Co., Ltd. Recent Development
7.10 Shanghai Pharmaceuticals
7.10.1 Shanghai Pharmaceuticals Company Information
7.10.2 Shanghai Pharmaceuticals Introduction and Business Overview
7.10.3 Shanghai Pharmaceuticals Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2019-2024)
7.10.4 Shanghai Pharmaceuticals Angiogenesis Therapeutic Agent Product Offerings
7.10.5 Shanghai Pharmaceuticals Recent Development
7.11 Johnson & Johnson
7.11.1 Johnson & Johnson Company Information
7.11.2 Johnson & Johnson Introduction and Business Overview
7.11.3 Johnson & Johnson Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2019-2024)
7.11.4 Johnson & Johnson Angiogenesis Therapeutic Agent Product Offerings
7.11.5 Johnson & Johnson Recent Development
7.12 Pfizer
7.12.1 Pfizer Company Information
7.12.2 Pfizer Introduction and Business Overview
7.12.3 Pfizer Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2019-2024)
7.12.4 Pfizer Angiogenesis Therapeutic Agent Product Offerings
7.12.5 Pfizer Recent Development
7.13 Sun Pharma
7.13.1 Sun Pharma Company Information
7.13.2 Sun Pharma Introduction and Business Overview
7.13.3 Sun Pharma Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2019-2024)
7.13.4 Sun Pharma Angiogenesis Therapeutic Agent Product Offerings
7.13.5 Sun Pharma Recent Development
7.14 Otsuka Pharmaceutical Co. Ltd
7.14.1 Otsuka Pharmaceutical Co. Ltd Company Information
7.14.2 Otsuka Pharmaceutical Co. Ltd Introduction and Business Overview
7.14.3 Otsuka Pharmaceutical Co. Ltd Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2019-2024)
7.14.4 Otsuka Pharmaceutical Co. Ltd Angiogenesis Therapeutic Agent Product Offerings
7.14.5 Otsuka Pharmaceutical Co. Ltd Recent Development
7.15 Daiichi Sankyo
7.15.1 Daiichi Sankyo Company Information
7.15.2 Daiichi Sankyo Introduction and Business Overview
7.15.3 Daiichi Sankyo Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2019-2024)
7.15.4 Daiichi Sankyo Angiogenesis Therapeutic Agent Product Offerings
7.15.5 Daiichi Sankyo Recent Development
7.16 ERC Labs
7.16.1 ERC Labs Company Information
7.16.2 ERC Labs Introduction and Business Overview
7.16.3 ERC Labs Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2019-2024)
7.16.4 ERC Labs Angiogenesis Therapeutic Agent Product Offerings
7.16.5 ERC Labs Recent Development
7.17 Medicom Health care
7.17.1 Medicom Health care Company Information
7.17.2 Medicom Health care Introduction and Business Overview
7.17.3 Medicom Health care Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2019-2024)
7.17.4 Medicom Health care Angiogenesis Therapeutic Agent Product Offerings
7.17.5 Medicom Health care Recent Development
7.18 Implandata ophthalmic products GmbH
7.18.1 Implandata ophthalmic products GmbH Company Information
7.18.2 Implandata ophthalmic products GmbH Introduction and Business Overview
7.18.3 Implandata ophthalmic products GmbH Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2019-2024)
7.18.4 Implandata ophthalmic products GmbH Angiogenesis Therapeutic Agent Product Offerings
7.18.5 Implandata ophthalmic products GmbH Recent Development
7.19 The Geuder Group, MORCHER GmbH
7.19.1 The Geuder Group, MORCHER GmbH Company Information
7.19.2 The Geuder Group, MORCHER GmbH Introduction and Business Overview
7.19.3 The Geuder Group, MORCHER GmbH Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2019-2024)
7.19.4 The Geuder Group, MORCHER GmbH Angiogenesis Therapeutic Agent Product Offerings
7.19.5 The Geuder Group, MORCHER GmbH Recent Development
7.20 Novamedika
7.20.1 Novamedika Company Information
7.20.2 Novamedika Introduction and Business Overview
7.20.3 Novamedika Angiogenesis Therapeutic Agent Sales, Revenue and Gross Margin (2019-2024)
7.20.4 Novamedika Angiogenesis Therapeutic Agent Product Offerings
7.20.5 Novamedika Recent Development
8 Industry Chain Analysis
8.1 Angiogenesis Therapeutic Agent Industrial Chain
8.2 Angiogenesis Therapeutic Agent Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Angiogenesis Therapeutic Agent Sales Model
8.5.2 Sales Channel
8.5.3 Angiogenesis Therapeutic Agent Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables
Table 1. Angiogenesis Therapeutic Agent Market Trends
Table 2. Angiogenesis Therapeutic Agent Market Drivers & Opportunity
Table 3. Angiogenesis Therapeutic Agent Market Challenges
Table 4. Angiogenesis Therapeutic Agent Market Restraints
Table 5. Global Angiogenesis Therapeutic Agent Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Angiogenesis Therapeutic Agent Revenue Market Share by Company (2019-2024)
Table 7. Global Angiogenesis Therapeutic Agent Sales Volume by Company (2019-2024) & (K Units)
Table 8. Global Angiogenesis Therapeutic Agent Sales Volume Market Share by Company (2019-2024)
Table 9. Global Market Angiogenesis Therapeutic Agent Price by Company (2019-2024) & (US$/Unit)
Table 10. Key Manufacturers Angiogenesis Therapeutic Agent Manufacturing Base Distribution and Headquarters
Table 11. Key Manufacturers Angiogenesis Therapeutic Agent Product Type
Table 12. Key Manufacturers Time to Begin Mass Production of Angiogenesis Therapeutic Agent
Table 13. Global Angiogenesis Therapeutic Agent Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Angiogenesis Therapeutic Agent as of 2023)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Global Angiogenesis Therapeutic Agent Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 17. Global Angiogenesis Therapeutic Agent Sales Value by Type (2019-2024) & (US$ Million)
Table 18. Global Angiogenesis Therapeutic Agent Sales Value by Type (2025-2030) & (US$ Million)
Table 19. Global Angiogenesis Therapeutic Agent Sales Market Share in Value by Type (2019-2024) & (%)
Table 20. Global Angiogenesis Therapeutic Agent Sales Market Share in Value by Type (2025-2030) & (%)
Table 21. Global Angiogenesis Therapeutic Agent Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)
Table 22. Global Angiogenesis Therapeutic Agent Sales Volume by Type (2019-2024) & (K Units)
Table 23. Global Angiogenesis Therapeutic Agent Sales Volume by Type (2025-2030) & (K Units)
Table 24. Global Angiogenesis Therapeutic Agent Sales Market Share in Volume by Type (2019-2024) & (%)
Table 25. Global Angiogenesis Therapeutic Agent Sales Market Share in Volume by Type (2025-2030) & (%)
Table 26. Global Angiogenesis Therapeutic Agent Price by Type (2019-2024) & (US$/Unit)
Table 27. Global Angiogenesis Therapeutic Agent Price by Type (2025-2030) & (US$/Unit)
Table 28. Global Angiogenesis Therapeutic Agent Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 29. Global Angiogenesis Therapeutic Agent Sales Value by Application (2019-2024) & (US$ Million)
Table 30. Global Angiogenesis Therapeutic Agent Sales Value by Application (2025-2030) & (US$ Million)
Table 31. Global Angiogenesis Therapeutic Agent Sales Market Share in Value by Application (2019-2024) & (%)
Table 32. Global Angiogenesis Therapeutic Agent Sales Market Share in Value by Application (2025-2030) & (%)
Table 33. Global Angiogenesis Therapeutic Agent Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)
Table 34. Global Angiogenesis Therapeutic Agent Sales Volume by Application (2019-2024) & (K Units)
Table 35. Global Angiogenesis Therapeutic Agent Sales Volume by Application (2025-2030) & (K Units)
Table 36. Global Angiogenesis Therapeutic Agent Sales Market Share in Volume by Application (2019-2024) & (%)
Table 37. Global Angiogenesis Therapeutic Agent Sales Market Share in Volume by Application (2025-2030) & (%)
Table 38. Global Angiogenesis Therapeutic Agent Price by Application (2019-2024) & (US$/Unit)
Table 39. Global Angiogenesis Therapeutic Agent Price by Application (2025-2030) & (US$/Unit)
Table 40. Global Angiogenesis Therapeutic Agent Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Global Angiogenesis Therapeutic Agent Sales Value by Region (2019-2024) & (US$ Million)
Table 42. Global Angiogenesis Therapeutic Agent Sales Value by Region (2025-2030) & (US$ Million)
Table 43. Global Angiogenesis Therapeutic Agent Sales Value by Region (2019-2024) & (%)
Table 44. Global Angiogenesis Therapeutic Agent Sales Value by Region (2025-2030) & (%)
Table 45. Global Angiogenesis Therapeutic Agent Sales Volume by Region (K Units): 2019 VS 2023 VS 2030
Table 46. Global Angiogenesis Therapeutic Agent Sales Volume by Region (2019-2024) & (K Units)
Table 47. Global Angiogenesis Therapeutic Agent Sales Volume by Region (2025-2030) & (K Units)
Table 48. Global Angiogenesis Therapeutic Agent Sales Volume by Region (2019-2024) & (%)
Table 49. Global Angiogenesis Therapeutic Agent Sales Volume by Region (2025-2030) & (%)
Table 50. Global Angiogenesis Therapeutic Agent Average Price by Region (2019-2024) & (US$/Unit)
Table 51. Global Angiogenesis Therapeutic Agent Average Price by Region (2025-2030) & (US$/Unit)
Table 52. Key Countries/Regions Angiogenesis Therapeutic Agent Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 53. Key Countries/Regions Angiogenesis Therapeutic Agent Sales Value, (2019-2024) & (US$ Million)
Table 54. Key Countries/Regions Angiogenesis Therapeutic Agent Sales Value, (2025-2030) & (US$ Million)
Table 55. Key Countries/Regions Angiogenesis Therapeutic Agent Sales Volume, (2019-2024) & (K Units)
Table 56. Key Countries/Regions Angiogenesis Therapeutic Agent Sales Volume, (2025-2030) & (K Units)
Table 57. Gilead Sciences, Inc. Company Information
Table 58. Gilead Sciences, Inc. Introduction and Business Overview
Table 59. Gilead Sciences, Inc. Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 60. Gilead Sciences, Inc. Angiogenesis Therapeutic Agent Product Offerings
Table 61. Gilead Sciences, Inc. Recent Development
Table 62. Eyetech Inc. Company Information
Table 63. Eyetech Inc. Introduction and Business Overview
Table 64. Eyetech Inc. Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 65. Eyetech Inc. Angiogenesis Therapeutic Agent Product Offerings
Table 66. Eyetech Inc. Recent Development
Table 67. Becton, Dickinson and Company Company Information
Table 68. Becton, Dickinson and Company Introduction and Business Overview
Table 69. Becton, Dickinson and Company Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 70. Becton, Dickinson and Company Angiogenesis Therapeutic Agent Product Offerings
Table 71. Becton, Dickinson and Company Recent Development
Table 72. Regeneron Pharmaceuticals, Inc. Company Information
Table 73. Regeneron Pharmaceuticals, Inc. Introduction and Business Overview
Table 74. Regeneron Pharmaceuticals, Inc. Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 75. Regeneron Pharmaceuticals, Inc. Angiogenesis Therapeutic Agent Product Offerings
Table 76. Regeneron Pharmaceuticals, Inc. Recent Development
Table 77. Genentech, Inc. Company Information
Table 78. Genentech, Inc. Introduction and Business Overview
Table 79. Genentech, Inc. Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 80. Genentech, Inc. Angiogenesis Therapeutic Agent Product Offerings
Table 81. Genentech, Inc. Recent Development
Table 82. Novartis AG Company Information
Table 83. Novartis AG Introduction and Business Overview
Table 84. Novartis AG Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 85. Novartis AG Angiogenesis Therapeutic Agent Product Offerings
Table 86. Novartis AG Recent Development
Table 87. Allergan plc Company Information
Table 88. Allergan plc Introduction and Business Overview
Table 89. Allergan plc Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 90. Allergan plc Angiogenesis Therapeutic Agent Product Offerings
Table 91. Allergan plc Recent Development
Table 92. Bayer AG Company Information
Table 93. Bayer AG Introduction and Business Overview
Table 94. Bayer AG Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 95. Bayer AG Angiogenesis Therapeutic Agent Product Offerings
Table 96. Bayer AG Recent Development
Table 97. Santen Pharmaceutical Co., Ltd. Company Information
Table 98. Santen Pharmaceutical Co., Ltd. Introduction and Business Overview
Table 99. Santen Pharmaceutical Co., Ltd. Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 100. Santen Pharmaceutical Co., Ltd. Angiogenesis Therapeutic Agent Product Offerings
Table 101. Santen Pharmaceutical Co., Ltd. Recent Development
Table 102. Shanghai Pharmaceuticals Company Information
Table 103. Shanghai Pharmaceuticals Introduction and Business Overview
Table 104. Shanghai Pharmaceuticals Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 105. Shanghai Pharmaceuticals Angiogenesis Therapeutic Agent Product Offerings
Table 106. Shanghai Pharmaceuticals Recent Development
Table 107. Johnson & Johnson Company Information
Table 108. Johnson & Johnson Introduction and Business Overview
Table 109. Johnson & Johnson Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 110. Johnson & Johnson Angiogenesis Therapeutic Agent Product Offerings
Table 111. Johnson & Johnson Recent Development
Table 112. Pfizer Company Information
Table 113. Pfizer Introduction and Business Overview
Table 114. Pfizer Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 115. Pfizer Angiogenesis Therapeutic Agent Product Offerings
Table 116. Pfizer Recent Development
Table 117. Sun Pharma Company Information
Table 118. Sun Pharma Introduction and Business Overview
Table 119. Sun Pharma Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 120. Sun Pharma Angiogenesis Therapeutic Agent Product Offerings
Table 121. Sun Pharma Recent Development
Table 122. Otsuka Pharmaceutical Co. Ltd Company Information
Table 123. Otsuka Pharmaceutical Co. Ltd Introduction and Business Overview
Table 124. Otsuka Pharmaceutical Co. Ltd Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 125. Otsuka Pharmaceutical Co. Ltd Angiogenesis Therapeutic Agent Product Offerings
Table 126. Otsuka Pharmaceutical Co. Ltd Recent Development
Table 127. Daiichi Sankyo Company Information
Table 128. Daiichi Sankyo Introduction and Business Overview
Table 129. Daiichi Sankyo Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 130. Daiichi Sankyo Angiogenesis Therapeutic Agent Product Offerings
Table 131. Daiichi Sankyo Recent Development
Table 132. ERC Labs Company Information
Table 133. ERC Labs Introduction and Business Overview
Table 134. ERC Labs Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 135. ERC Labs Angiogenesis Therapeutic Agent Product Offerings
Table 136. ERC Labs Recent Development
Table 137. Medicom Health care Company Information
Table 138. Medicom Health care Introduction and Business Overview
Table 139. Medicom Health care Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 140. Medicom Health care Angiogenesis Therapeutic Agent Product Offerings
Table 141. Medicom Health care Recent Development
Table 142. Implandata ophthalmic products GmbH Company Information
Table 143. Implandata ophthalmic products GmbH Introduction and Business Overview
Table 144. Implandata ophthalmic products GmbH Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 145. Implandata ophthalmic products GmbH Angiogenesis Therapeutic Agent Product Offerings
Table 146. Implandata ophthalmic products GmbH Recent Development
Table 147. The Geuder Group, MORCHER GmbH Company Information
Table 148. The Geuder Group, MORCHER GmbH Introduction and Business Overview
Table 149. The Geuder Group, MORCHER GmbH Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 150. The Geuder Group, MORCHER GmbH Angiogenesis Therapeutic Agent Product Offerings
Table 151. The Geuder Group, MORCHER GmbH Recent Development
Table 152. Novamedika Company Information
Table 153. Novamedika Introduction and Business Overview
Table 154. Novamedika Angiogenesis Therapeutic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 155. Novamedika Angiogenesis Therapeutic Agent Product Offerings
Table 156. Novamedika Recent Development
Table 157. Key Raw Materials Lists
Table 158. Raw Materials Key Suppliers Lists
Table 159. Angiogenesis Therapeutic Agent Downstream Customers
Table 160. Angiogenesis Therapeutic Agent Distributors List
Table 161. Research Programs/Design for This Report
Table 162. Key Data Information from Secondary Sources
Table 163. Key Data Information from Primary Sources
List of Figures
Figure 1. Angiogenesis Therapeutic Agent Product Picture
Figure 2. Global Angiogenesis Therapeutic Agent Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Angiogenesis Therapeutic Agent Sales Value (2019-2030) & (US$ Million)
Figure 4. Global Angiogenesis Therapeutic Agent Sales Volume (2019-2030) & (K Units)
Figure 5. Global Angiogenesis Therapeutic Agent Sales Price (2019-2030) & (US$/Unit)
Figure 6. Angiogenesis Therapeutic Agent Report Years Considered
Figure 7. Global Angiogenesis Therapeutic Agent Players Revenue Ranking (2023) & (US$ Million)
Figure 8. Global Angiogenesis Therapeutic Agent Players Sales Volume Ranking (2023) & (K Units)
Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Angiogenesis Therapeutic Agent Revenue in 2023
Figure 10. Angiogenesis Therapeutic Agent Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 11. Myopic Choroidal Neovascularization Picture
Figure 12. Macular Edema Picture
Figure 13. Diabetic Retinopathy Picture
Figure 14. Macular Degeneration Picture
Figure 15. Global Angiogenesis Therapeutic Agent Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 16. Global Angiogenesis Therapeutic Agent Sales Value Market Share by Type, 2023 & 2030
Figure 17. Global Angiogenesis Therapeutic Agent Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)
Figure 18. Global Angiogenesis Therapeutic Agent Sales Volume Market Share by Type, 2023 & 2030
Figure 19. Global Angiogenesis Therapeutic Agent Price by Type (2019-2030) & (US$/Unit)
Figure 20. Product Picture of Retail Pharmacies
Figure 21. Product Picture of Online Pharmacies
Figure 22. Product Picture of Hospital Pharmacies
Figure 23. Global Angiogenesis Therapeutic Agent Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 24. Global Angiogenesis Therapeutic Agent Sales Value Market Share by Application, 2023 & 2030
Figure 25. Global Angiogenesis Therapeutic Agent Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)
Figure 26. Global Angiogenesis Therapeutic Agent Sales Volume Market Share by Application, 2023 & 2030
Figure 27. Global Angiogenesis Therapeutic Agent Price by Application (2019-2030) & (US$/Unit)
Figure 28. North America Angiogenesis Therapeutic Agent Sales Value (2019-2030) & (US$ Million)
Figure 29. North America Angiogenesis Therapeutic Agent Sales Value by Country (%), 2023 VS 2030
Figure 30. Europe Angiogenesis Therapeutic Agent Sales Value (2019-2030) & (US$ Million)
Figure 31. Europe Angiogenesis Therapeutic Agent Sales Value by Country (%), 2023 VS 2030
Figure 32. Asia Pacific Angiogenesis Therapeutic Agent Sales Value (2019-2030) & (US$ Million)
Figure 33. Asia Pacific Angiogenesis Therapeutic Agent Sales Value by Country (%), 2023 VS 2030
Figure 34. South America Angiogenesis Therapeutic Agent Sales Value (2019-2030) & (US$ Million)
Figure 35. South America Angiogenesis Therapeutic Agent Sales Value by Country (%), 2023 VS 2030
Figure 36. Middle East & Africa Angiogenesis Therapeutic Agent Sales Value (2019-2030) & (US$ Million)
Figure 37. Middle East & Africa Angiogenesis Therapeutic Agent Sales Value by Country (%), 2023 VS 2030
Figure 38. Key Countries/Regions Angiogenesis Therapeutic Agent Sales Value (%), (2019-2030)
Figure 39. Key Countries/Regions Angiogenesis Therapeutic Agent Sales Volume (%), (2019-2030)
Figure 40. United States Angiogenesis Therapeutic Agent Sales Value, (2019-2030) & (US$ Million)
Figure 41. United States Angiogenesis Therapeutic Agent Sales Value by Type (%), 2023 VS 2030
Figure 42. United States Angiogenesis Therapeutic Agent Sales Value by Application (%), 2023 VS 2030
Figure 43. Europe Angiogenesis Therapeutic Agent Sales Value, (2019-2030) & (US$ Million)
Figure 44. Europe Angiogenesis Therapeutic Agent Sales Value by Type (%), 2023 VS 2030
Figure 45. Europe Angiogenesis Therapeutic Agent Sales Value by Application (%), 2023 VS 2030
Figure 46. China Angiogenesis Therapeutic Agent Sales Value, (2019-2030) & (US$ Million)
Figure 47. China Angiogenesis Therapeutic Agent Sales Value by Type (%), 2023 VS 2030
Figure 48. China Angiogenesis Therapeutic Agent Sales Value by Application (%), 2023 VS 2030
Figure 49. Japan Angiogenesis Therapeutic Agent Sales Value, (2019-2030) & (US$ Million)
Figure 50. Japan Angiogenesis Therapeutic Agent Sales Value by Type (%), 2023 VS 2030
Figure 51. Japan Angiogenesis Therapeutic Agent Sales Value by Application (%), 2023 VS 2030
Figure 52. South Korea Angiogenesis Therapeutic Agent Sales Value, (2019-2030) & (US$ Million)
Figure 53. South Korea Angiogenesis Therapeutic Agent Sales Value by Type (%), 2023 VS 2030
Figure 54. South Korea Angiogenesis Therapeutic Agent Sales Value by Application (%), 2023 VS 2030
Figure 55. Southeast Asia Angiogenesis Therapeutic Agent Sales Value, (2019-2030) & (US$ Million)
Figure 56. Southeast Asia Angiogenesis Therapeutic Agent Sales Value by Type (%), 2023 VS 2030
Figure 57. Southeast Asia Angiogenesis Therapeutic Agent Sales Value by Application (%), 2023 VS 2030
Figure 58. India Angiogenesis Therapeutic Agent Sales Value, (2019-2030) & (US$ Million)
Figure 59. India Angiogenesis Therapeutic Agent Sales Value by Type (%), 2023 VS 2030
Figure 60. India Angiogenesis Therapeutic Agent Sales Value by Application (%), 2023 VS 2030
Figure 61. Angiogenesis Therapeutic Agent Industrial Chain
Figure 62. Angiogenesis Therapeutic Agent Manufacturing Cost Structure
Figure 63. Channels of Distribution (Direct Sales, and Distribution)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
